Novo Nordisk sues Eli Lilly over allegedly misleading GLP-1 drug ads

Reuters2026/07/21 11:35

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novo Nordisk filed a federal lawsuit in New Jersey accusing Eli Lilly of false advertising in US consumer campaigns for Zepbound and Mounjaro.
Complaint targets comparisons using Lilly’s highest doses against lower doses of Wegovy and Ozempic, omitting newer, more effective options.
Novo argues ads exclude Wegovy 7.2 mg, cleared by the FDA in March 2026, which showed 18.8% average weight loss in a 72-week trial.
Suit seeks a permanent injunction to pull the comparative ads across platforms, backed by a corrective advertising campaign.
Novo signaled it may seek a preliminary injunction in the coming days to immediately block the advertising.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210735OMX_____CNEWS_EN_GNW1001213727_en) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novo Nordisk sues Eli Lilly over allegedly misleading GLP-1 drug ads

You may also like

Crypto prices